Abstract:Background: Clinical guidelines recommend type 2 diabetes (T2DM) patients with contraindications or intolerance of metformin to consider a glucose-lowering agent from another class as initial monotherapy. The availability of multiple alternative agents increases the complexity of clinical drug use. However, little systematic data is available for these agents as monotherapy for T2DM. This study aims to estimate and compare the efficacy and safety of eight commonly-used classes of glucose-lowering agents as monotherapy for T2DM. Methods: Systematic review was conducted by searching eight English and Chinese databases to identify randomized controlled trials (1990-2016) comparing treatment effect of a glucose-lowering agent with placebo/lifestyle-intervention in Chinese patients. The agents included metformin, sulfonylurea, thiazolidinedione, α-glucosidase inhibitor, glinide, DPP-4 inhibitor, GLP-1 receptor agonist, and insulin. They were firstly compared with placebo/lifestyle-intervention using meta-analysis, then compared against each other using indirect treatment comparison with placebo/lifestyle-intervention as common comparator. Findings: 46 studies were included. The agents significantly reduced HbA1c level by 0·69% to 2·37% compared with placebo/lifestyle-intervention. Comparing them against each other, insulin was most efficacious while glinide was most inefficacious in reducing HbA1c, metformin was most efficacious while sulfonylurea was most inefficacious in reducing BMI and TC, thiazolidinedione was most efficacious while α-glucosidase inhibitor was most inefficacious in increasing HDL-C. The agents (except sulfonylurea and insulin) had no significant differences on hypoglycemia risks. Only metformin and GLP-1 receptor agonist achieved a comprehensive control on multiple outcomes including HbA1c, BMI, TC and HDL-C. Interpretation: Treatment effect varied by agents. Our results, along with individualized patient factors, preferences and needs, should be considered when selecting an agent in clinical practice. Funding Statement: The authors stated there was no funding source for this study. Declaration of Interests: The authors declare no competing interests. Ethics Approval Statement: This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.

Efficacy and Safety of Eight Classes of Glucose-Lowering Agents As Monotherapy for Type 2 Diabetes: A Systematic Review and Indirect Treatment Comparison